Search results
Showing 1 to 8 of 8 results for setmelanotide
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542
In development Reference number: GID-TA11525 Expected publication date: 10 February 2027
We are listening to your views on this Technology appraisal guidance. Comments close 16 January 2026.
See a complete list of all our guidance and quality standards currently open for consultation
Awaiting development Reference number: GID-HST10067 Expected publication date: TBC
Our forward view highlights the topics we will prioritise in the coming year.